EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 143 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... June 24, 2021 Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... February 18, 2025 Co-Existing with COVID-19: Should I go back to work? Do I... June 19, 2020 Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... September 28, 2022 Load more HOT NEWS Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors New drug available for rare thyroid cancer on NHS in England Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts...
